Antisoma's AS1404 combined with Erbitux in preclinical study

By E. Janene Geiss

Philadelphia, Sept. 12 - Antisoma said Tuesday that data showed combining Antisoma's AS1404 with the anti-EGF-receptor antibody Erbitux (cetuximab) produces a synergistic reduction in the growth of lung cancer xenografts.

This adds another targeted therapy to the list of agents with which AS1404 has been successfully combined, the London biopharmaceutical company said in a news release.

The new data were presented Tuesday at a seminar held by Antisoma and Cancer Research Technology, the development and commercialization company of Cancer Research UK.

The company said its focus is moving AS1404 into phase 3 trials in combination with chemotherapy as an anticancer treatment.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.